EnBio Holdings, Inc. (6092) AI Stock Analysis

• Market Cap: ¥5.22B
• Dividend Yield: 1.54%
• Average Volume (3M): 25.91K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.65
• Revenue Growth: 3.37%
• EPS Growth: -27.47%
• Country: JP
• Employees: 104
• Sector: Industrials
• Sector Strength: 72
• Industry: Specialty Business Services
• EPS (TTM): -75.25
• Shares Outstanding: 8,175,200
• 10 Day Avg. Volume: 21,320
• 30 Day Avg. Volume: 25,910
• PEG Ratio: -0.29
• Price to Book (P/B): 0.53
• Price to Sales (P/S): 0.45
• P/FCF Ratio: -3.37
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 66 Neutral
• Price Target: ¥751.00 ▲(25.59% Upside)
• Action: Reiterated Date: 02/25/26
• Date: Action: Reiterated 02/25/26

The score is driven primarily by solid financial performance fundamentals (revenue growth and healthy operating margins) but is held back by weak cash flow quality (negative free cash flow and low operating cash flow vs. net income). Technicals are supportive with a clear uptrend, though overbought indicators add near-term risk. Valuation is a drag due to a negative P/E and only a modest dividend yield.

Positive Factors

Revenue Growth

Consistent revenue growth of ~11.4% across the latest fiscal year indicates durable demand and successful commercial execution. Over a 2-6 month horizon this supports market position, underwriting of ongoing investments, and a stronger base for margin expansion or reinvestment.

Operational Margins

Healthy EBIT and EBITDA margins (7.95% and 12.58%) reflect operational efficiency and pricing power in core services. Sustained mid-teens EBITDA-like margins provide durable cash-earnings capacity to fund growth, service debt and absorb industry cycles over months to quarters.

Balanced Capital Structure

A debt-to-equity near 1.10 and a ~43% equity ratio indicate a conservative, balanced leverage profile. This structure provides financial flexibility to fund capex or M&A, helps preserve liquidity in downturns, and reduces refinancing risk over the medium term.

Negative Factors

Weak Cash Conversion

Negative free cash flow and an operating-cash-to-net-income ratio of 0.05 show poor cash conversion and high capex demands. Persistently weak cash generation can force external financing, constrain reinvestment, and limit ability to sustainably fund dividends or deleveraging.

Falling Profitability

A decline in net income alongside a modest 4.24% net margin signals pressure on bottom-line profitability. If structural, this reduces retained earnings and weakens the company's ability to build reserves or invest in growth initiatives, affecting long-term resilience.

Low Return on Equity

ROE of ~4.95% indicates limited efficiency in converting equity into profits. Over time, low ROE can deter capital allocation, signal weak competitive returns versus peers, and constrain shareholder value creation absent operational or strategic improvement.

EnBio Holdings, Inc. Business Overview & Revenue Model

Company Description

EnBio Holdings Co., Ltd. engages in soil and groundwater contamination, and renewable energy businesses in Japan. It imports and sells equipment, materials, and cleaning agents; and purchases, sells, and leases contaminated land. The company is also involved in solar power; biomass power generation; renewable energy power generation; water resource development; and ethical consumption promotion businesses. EnBio Holdings Co., Ltd. was incorporated in 1999 and is headquartered in Tokyo, Japan.

How the Company Makes Money

EnBio Holdings generates revenue through multiple streams, primarily from the sale of its biopharmaceutical products and medical devices. The company engages in direct sales to healthcare providers, hospitals, and clinics, as well as through partnerships with larger pharmaceutical companies that distribute its products. Additionally, EnBio may earn revenue from licensing agreements, where it licenses its technology or products to other firms for a fee or royalties. The company also potentially benefits from government grants and research funding, which support its R&D efforts and product development initiatives.

EnBio Holdings, Inc. Financial Statement Overview

Summary

Strong revenue growth (+11.44% from 2024 to 2025) and healthy EBIT/EBITDA margins (7.95%/12.58%) support the score, but profitability weakened with net income declining and cash generation is a key concern as free cash flow turned negative in 2025 and operating cash flow relative to net income is very low (0.05). The balance sheet is stable with a balanced debt-to-equity (1.10) and a 43.14% equity ratio, though ROE is modest (4.95%).

Income Statement

EnBio Holdings, Inc. shows a robust performance with strong revenue growth of 11.44% from 2024 to 2025, indicating positive business momentum. The gross profit margin stands at 24.87% and the net profit margin at 4.24% for 2025, which are moderate but consistent over the years. However, the decline in net income from 2024 to 2025 suggests some pressure on profitability. The EBIT and EBITDA margins are healthy at 7.95% and 12.58%, respectively, reflecting efficient operational management.

Balance Sheet

The balance sheet of EnBio Holdings, Inc. reveals a solid equity base with a debt-to-equity ratio of 1.10, indicating a balanced capital structure. The return on equity (ROE) is relatively low at 4.95% for 2025, showing room for improvement in generating returns for shareholders. The equity ratio is 43.14%, suggesting a stable financial position with a reasonable level of leverage.

Cash Flow

The cash flow statement indicates challenges with free cash flow, which turned negative in 2025, driven by high capital expenditures. The operating cash flow to net income ratio is low at 0.05, highlighting potential inefficiencies in cash generation relative to net income. However, the company has maintained positive operating cash flow, which is a positive indicator of ongoing operational health.

Breakdown	TTM	Mar 2025	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	10.11B	10.67B	9.58B	8.12B	8.99B	6.84B
Gross Profit	2.45B	2.65B	2.48B	2.76B	2.43B	1.89B
EBITDA	668.74M	1.34B	1.62B	1.76B	1.57B	981.00M
Net Income	109.69M	452.69M	708.76M	812.06M	654.05M	304.06M
Balance Sheet
Total Assets	21.56B	21.20B	19.31B	17.35B	16.37B	15.70B
Cash, Cash Equivalents and Short-Term Investments	3.19B	3.29B	3.60B	2.83B	2.37B	2.02B
Total Debt	10.28B	10.10B	8.62B	8.90B	8.58B	9.04B
Total Liabilities	12.32B	11.96B	10.72B	10.49B	10.40B	10.38B
Stockholders Equity	9.15B	9.14B	8.49B	6.79B	5.89B	5.29B
Cash Flow
Free Cash Flow	0.00	-1.44B	584.36M	824.13M	1.25B	-1.43B
Operating Cash Flow	0.00	21.92M	1.66B	1.99B	2.41B	297.16M
Investing Cash Flow	0.00	-1.60B	-1.58B	-1.77B	-1.48B	-2.16B
Financing Cash Flow	0.00	1.27B	638.92M	240.73M	-534.92M	928.54M

EnBio Holdings, Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 598.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6092, the sentiment is Neutral. The current price of 598 is below the 20-day moving average (MA) of 648.45, below the 50-day MA of 626.74, and below the 200-day MA of 620.51, indicating a neutral trend. The MACD of 15.74 indicates Negative momentum. The RSI at 47.87 is Neutral, neither overbought nor oversold. The STOCH value of 55.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:6092.

EnBio Holdings, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
9791	74 Outperform	¥10.61B	8.19	―	2.33%	-6.09%	24.42%
4809	72 Outperform	¥20.34B	9.94	―	3.27%	7.63%	11.84%
7987	69 Neutral	¥16.23B	8.30	―	3.79%	-0.03%	84.08%
6092	66 Neutral	¥5.22B	-29.16	―	1.54%	3.37%	-27.47%
9325	65 Neutral	¥12.65B	14.87	―	2.63%	18.27%	-4.07%
Sector *	63 Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%
7049	62 Neutral	¥6.60B	14.96	―	―	24.34%	80.81%

EnBio Holdings, Inc. Corporate Events

EnBio Holdings Lifts Sales and Operating Profit but Slides to Net Loss for Nine-Month Period

EnBio Holdings reported consolidated net sales of ¥9.1 billion for the nine months ended Dec. 31, 2025, up 11.1% year on year, with operating profit rising 33.1% to ¥1.1 billion and ordinary profit up 25.7% to ¥1.09 billion. Despite these gains, the company swung to a net loss attributable to owners of the parent of ¥65 million, compared with a ¥565 million profit a year earlier, while net assets slipped and the equity ratio declined to 40.6%.

For the full year ending March 31, 2026, EnBio forecasts a 20% increase in net sales to ¥12.8 billion and an 88.2% jump in ordinary profit, but expects full-year profit attributable to owners of the parent to plunge 77.9% to ¥100 million. The group also confirmed its annual dividend forecast of ¥9 per share and noted a change in reporting units to millions of yen, suggesting continued shareholder returns even as earnings volatility and balance sheet pressure weigh on its financial profile.

The most recent analyst rating on (JP:6092) stock is a Hold with a Yen648.00 price target. To see the full list of analyst forecasts on EnBio Holdings, Inc. stock, see the JP:6092 Stock Forecast page.